{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:14Z","timestamp":1788174554901,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1093\/annonc\/mdm511","type":"journal-article","created":{"date-parts":[[2007,12,15]],"date-time":"2007-12-15T01:22:25Z","timestamp":1197681745000},"page":"553-559","source":"Crossref","is-referenced-by-count":17,"title":["The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"M.J.","family":"Overman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm511_bb0010","series-title":"Non-Hodgkin's Lymphoma","author":"Armitage","year":"2001"},{"key":"10.1093\/annonc\/mdm511_bb0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [editorial]","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm511_bb0025","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0030","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project [editorial]","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm511_bb0035","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0040","series-title":"Follicular Lymphoma","author":"Nathwani","year":"1994"},{"key":"10.1093\/annonc\/mdm511_bb0045","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0050","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","article-title":"Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Wendum","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19820301)49:5<840::AID-CNCR2820490503>3.0.CO;2-9","article-title":"Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy","volume":"49","author":"Glick","year":"1982","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm511_bb0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood.V56.1.98.98","article-title":"Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival","volume":"56","author":"Osborne","year":"1980","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0065","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.1994.12.7.1349","article-title":"Follicular large-cell lymphoma: intermediate or low grade?","volume":"12","author":"Bartlett","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0070","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/JCO.1984.2.7.811","article-title":"Follicular large cell lymphoma: analysis and prognostic factors in 62 patients","volume":"2","author":"Kantarjian","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0080","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/1042819031000123564","article-title":"The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases","volume":"44","author":"Rigacci","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdm511_bb0085","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0090","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0095","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0100","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0110","article-title":"A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma","volume":"122","author":"Sarma","year":"2004","journal-title":"ASCO Annual Meeting Proceedings (Post-Meeting Edition)"},{"key":"10.1093\/annonc\/mdm511_bb0115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","article-title":"Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model","volume":"9","author":"Romaguera","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0120","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0125","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1182\/blood-2005-01-0053","article-title":"Does the FLIPI apply to grade 3 follicular lymphoma?","volume":"105","author":"Ghielmini","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2003.18.114","article-title":"Something old, something few, something subjective, something deja vu","volume":"21","author":"Horning","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6601006","article-title":"Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?","volume":"89","author":"Chau","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm511_bb0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdm511_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm511_bb0150","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0155","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V101.3.1149","article-title":"Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive","volume":"101","author":"Bosga-Bouwer","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm511_bb0160","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","article-title":"Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study","volume":"107","author":"Winter","year":"2006","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/3\/553\/684219\/mdm511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:55:58Z","timestamp":1624442158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419411782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0923753419411782"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm511","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}